Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside

Company Overview - Absci Corporation ABSI is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins [1] - The company focuses on creating first-in-class or best-in-class therapies, progressing them from discovery to early clinical trials [5] - Absci plans to partner with other companies for commercialization after proving the concept in clinical trials [5] Core Technologies - Absci leverages its proprietary synthetic biology technology (SoluPro) to generate large experimental datasets internally, which are refined using AI/ML [2] - The company's core technologies, SoluPro and ACE, are essential for a successful tech-bio company, generating large-scale, well-documented binding affinity data for biologics [3] Strategic Collaborations - Absci has entered into a strategic collaboration with Advanced Micro Devices Inc AMD to enhance its AI drug discovery capabilities [2] - The company works with pharmaceutical partners like Merck & Co Inc MRK, Almirall SA, and AstraZeneca Plc AZN on early-stage projects, providing milestone payments and royalties [6] Product Development - Absci has demonstrated the ability to rapidly develop indication-agnostic leads while focusing on highly optimized agents to reduce downstream clinical failure [3] - The company showcased its capability by the rapid development of its TL1A candidate, ABS-101, through an iterative process combining robust data with AI/ML [4] Financial and Market Performance - Needham analyst has initiated coverage on Absci with a Buy rating and a price forecast of $9 [4] - ABSI stock is up 23% at $3 96 at the last check on Wednesday [6] Value Proposition - Absci builds its value through proprietary assets developed in-house, such as ABS-101, 201, 301, and 501 [4] - The company's approach allows it to quickly advance and monetize clinical-stage assets, aligning well with its AI/ML-driven platform [6]